SANES

10.796

+1.22%↑

BBVA

20.08

+1.03%↑

BNP

92.39

+0.5%↑

CABK

11.66

+0.52%↑

INGA

27.165

+1.04%↑

SANES

10.796

+1.22%↑

BBVA

20.08

+1.03%↑

BNP

92.39

+0.5%↑

CABK

11.66

+0.52%↑

INGA

27.165

+1.04%↑

SANES

10.796

+1.22%↑

BBVA

20.08

+1.03%↑

BNP

92.39

+0.5%↑

CABK

11.66

+0.52%↑

INGA

27.165

+1.04%↑

SANES

10.796

+1.22%↑

BBVA

20.08

+1.03%↑

BNP

92.39

+0.5%↑

CABK

11.66

+0.52%↑

INGA

27.165

+1.04%↑

SANES

10.796

+1.22%↑

BBVA

20.08

+1.03%↑

BNP

92.39

+0.5%↑

CABK

11.66

+0.52%↑

INGA

27.165

+1.04%↑

Начало・Списък с акции・DBV Technologies SA

D
DBV Technologies SA

Отворен

3.256 0.74

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.204

Максимум

3.354

Ключови измерители
By Trading Economics
Приходи	-2.4M -48M
EPS	-0.095
Марж на печалбата	-1,323.179
Служители	161
EBITDA	-4.1M -46M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+2.52% upside

Дивиденти
By Dow Jones
Следващи печалби	29.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-70M 969M
Предишно отваряне	2.52
Предишно затваряне	3.256

DBV Technologies SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.05.2026 г., 08:24 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25.05.2026 г., 21:22 ч. UTC

Печалби

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Basic Materials Roundup: Market Talk

25.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Basic Materials Roundup: Market Talk

25.05.2026 г., 16:01 ч. UTC

Пазарно говорене

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25.05.2026 г., 14:43 ч. UTC

Пазарно говорене

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25.05.2026 г., 14:15 ч. UTC

Пазарно говорене

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25.05.2026 г., 13:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

25.05.2026 г., 12:58 ч. UTC

Пазарно говорене

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25.05.2026 г., 12:56 ч. UTC

Пазарно говорене

Печалби

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25.05.2026 г., 12:48 ч. UTC

Пазарно говорене

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25.05.2026 г., 12:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.05.2026 г., 12:34 ч. UTC

Пазарно говорене

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25.05.2026 г., 12:10 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Delivery Hero's Assets Look Strategic -- Market Talk

25.05.2026 г., 11:00 ч. UTC

Пазарно говорене

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25.05.2026 г., 10:19 ч. UTC

Пазарно говорене

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25.05.2026 г., 10:05 ч. UTC

Печалби

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25.05.2026 г., 10:04 ч. UTC

Печалби

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25.05.2026 г., 10:03 ч. UTC

Печалби

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25.05.2026 г., 10:02 ч. UTC

Печалби

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25.05.2026 г., 10:01 ч. UTC

Печалби

Tenaga Nasional 1Q Net Up 3.7% on Year

25.05.2026 г., 10:00 ч. UTC

Печалби

Tenaga Nasional 1Q Rev Up 6.6% on Year

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q EPS MYR0.1883

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q Rev MYR17.1B

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q Net MYR1.1B

25.05.2026 г., 09:38 ч. UTC

Пазарно говорене

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25.05.2026 г., 09:33 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

25.05.2026 г., 09:33 ч. UTC

Пазарно говорене

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25.05.2026 г., 08:55 ч. UTC

Пазарно говорене

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

DBV Technologies SA Прогноза

Ценова цел

By TipRanks

2.52% нагоре

12-месечна прогноза

Среден 3.26 EUR 2.52%

Висок 5.5 EUR

Нисък 1.01 EUR

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за DBV Technologies SA през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на DBV Technologies SA през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.